問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (非在職)

Digestive System Department

Division of General Internal Medicine

更新時間：2023-09-19

沈一嫻Sheen, I-Shyan
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 10 個月

Recruiting Trial

10Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

沈一嫻

List

59Cases

-

Phase I

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

2005-10-01 - 2007-09-30

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2010-07-15 - 2012-06-15

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2014-04-20 - 2016-05-20

Phase II

Completed
Randomized, Open Label, Phase 2 Trial of ADI-PEG 20 plus Concurrent Transarterial Chemoembolization (TACE) Versus TACE Alone in Patients with Unresectable Hepatocellular Carcinoma

  • Condition/Disease

    Unresectable Hepatocellular Carcinoma

  • Test Drug

    ADI-PEG 20

Participate Sites
4Sites

Terminated3Sites

Study ended1Sites

鄭隆賓
China Medical University Hospital

Division of General Surgery

2006-10-18 - 2008-06-30

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2009-04-01 - 2010-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2010-08-01 - 2014-12-31

Others

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2013-01-15 - 2016-12-31

Phase II

Study to evaluate safety, tolerability, pharmacokinetics, and antiviral activity of ritonavir-boosted danoprevir in combination with peginterferon alfa-2a plus ribavirin in treatment-naïve patients of asian origin who have chronic hepatitis c genotype 1 with or without COMPENSATED cirrhosis

  • Condition/Disease

    chronic Hepatitis C

  • Test Drug

    Danoprevir (DNV) plus ritonavir (RTV)

Participate Sites
6Sites

Terminated6Sites

2004-12-01 - 2008-01-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2011-07-01 - 2013-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Study ended11Sites

1 2 3 4 5 6
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB